comscoreResearch News

Research News

Find out what the latest clinical trial results mean for you.
More from this topic
1389 Research news
FDA Approves Enhertu for Unresectable or Metastatic HER2-Low Breast Cancer

On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer.

Aug 5, 2022 | Targeted Therapy and Diagnosis
FDA Approves Keytruda for Early-Stage Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved Keytruda plus chemotherapy before surgery, followed by Keytruda alone after surgery to treat early-stage triple-negative breast cancer with a high risk of recurrence.

Jul 27, 2021 | Diagnosis and Immunotherapy
Keytruda Before and After Surgery Improves Outcomes in Early-Stage Triple-Negative Breast Cancer

The immunotherapy medicine Keytruda plus chemotherapy before surgery and Keytruda alone after surgery improved event-free survival better than chemotherapy alone in women diagnosed with early-stage triple-negative breast cancer.

After 5 Years of Hormonal Therapy, 2 More Years of Arimidex Offers Same Benefits As 5 More Years for Postmenopausal Women With Early-Stage Breast Cancer

After taking 5 years of hormonal therapy following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer got the same benefits from taking 2 more years of Arimidex as they did from taking 5 more years, with fewer side effects.

Aug 6, 2021 | Diagnosis and Hormonal Therapy
Treatment Break From Extended Femara Doesn’t Affect Survival

Survival rates were the same in postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer whether they took a short treatment break during extended adjuvant hormonal therapy with Femara or took Femara continuously for 5 years after previously taking hormonal therapy for an initial 5 years.

Aug 17, 2021 | Diagnosis and Hormonal Therapy
Genentech Withdraws Breast Cancer Indication From Tecentriq

On Aug. 27, 2021, Genentech announced it is voluntarily withdrawing the breast cancer indication from the immunotherapy medicine Tecentriq in the United States.

Aug 28, 2021 | Diagnosis and Immunotherapy
Six Months After Second Pfizer Vaccine Dose, People With Solid Tumors Have Same COVID-19 Antibody Levels as People Without Cancer

Six months after receiving their second dose of the Pfizer COVID-19 vaccine, people diagnosed with solid tumor cancers had about the same antibody levels as people who hadn’t been diagnosed with cancer.

Adding Surgery to Treatment Plan Offers Better Survival for Certain Women Diagnosed With Stage IV Breast Cancer

A combination of surgery and systemic therapy can improve survival more than systemic therapy alone for women diagnosed with stage IV breast cancer with known hormone receptor and HER2 status.

Sep 20, 2021 | Diagnosis and Surgery
Adding Carboplatin to Chemotherapy Before Surgery Improves Early-Stage Triple-Negative Breast Cancer Outcomes

Adding carboplatin (brand name: Paraplatin) to the standard neoadjuvant chemotherapy regimen for early-stage triple-negative breast cancer improved event-free survival.

Supervised Exercise Safe for People With Bone Metastases

People diagnosed with metastatic cancer that has spread to the bones can safely participate in supervised exercise programs, according to a review of 17 studies.

Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer

Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.

Sep 22, 2021 | Diagnosis and Targeted Therapy
After 2-3 Years of Tamoxifen, 5 Years of Femara Offers More Benefits Than 2-3 Years

After taking tamoxifen for 2 to 3 years following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer had a better survival rate from taking 5 years of Femara rather than 2 to 3 years of Femara.

Sep 30, 2021 | Diagnosis and Hormonal Therapy
Knowing Moms’ Hereditary Cancer Risk Doesn’t Affect Kids’ Quality of Life

Telling children that their mothers have a genetic risk of developing breast and ovarian cancer doesn’t affect their long-term quality of life.

Oral Paclitaxel Plus Encequidar Offers Better Response Than IV Paclitaxel in Metastatic Breast Cancer

Metastatic breast cancer responded better to a combination of the chemotherapy medicine paclitaxel in pill form and encequidar (a medicine that allows oral paclitaxel to be absorbed into the bloodstream) than to intravenous paclitaxel.

Aug 5, 2022 | Chemotherapy and Diagnosis
Women With Breast Cancer Gene Mutation Have Same or Better Survival as Women Without Mutation

Women with a genetic mutation linked to a higher cancer risk who are diagnosed with breast cancer or ovarian cancer and receive chemotherapy treatment have the same or better survival rates as women who don’t have a genetic mutation linked to higher risk.

Chemo Brain Less Likely in Women Who Exercise

Women diagnosed with breast cancer who exercised before, during, and after chemotherapy were less likely to have chemo brain.

Aug 31, 2021 | Diagnosis, Chemotherapy and Exercise
Guidelines Help Oncologists Provide Individualized Palliative Care for People Diagnosed With Metastatic Breast Cancer

General oncologists have received new specific, practical recommendations on how to offer individualized palliative care to people diagnosed with metastatic breast cancer.

FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer

On Dec. 20, 2019, the U.S. Food and Drug Administration approved Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki) to treat people diagnosed with unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies.

Jan 2, 2020 | Diagnosis and Targeted Therapy
A New Standard of Care? Enhertu Improves Survival in People With Metastatic HER2-Low Breast Cancer

Compared with doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.

Breast Cancer Screening Declined Sharply When Pandemic Started

A new study by the Centers for Disease Control and Prevention echoes the results of other studies: Breast cancer screening rates dropped dramatically at the beginning of the COVID-19 pandemic, especially among women of certain racial and ethnic groups.

Jul 23, 2021 | Screening and Testing
Experimental Immunotherapy Medicine Works Similarly in Black and White Women With Triple-Negative Breast Cancer

When more Black women diagnosed with early-stage, triple-negative breast cancer joined a study on Imfinzi, the results showed the immunotherapy was as effective in Black women as it was in women of other races and ethnicities.

Aug 5, 2022 | Diagnosis, Ethnicity and Immunotherapy
Risk of Heart Problems Lower in Breast Cancer Survivors Who Exercise

Exercise helped reduce the risk of heart problems in women receiving treatment for breast cancer.

Hormone-Free Medicine for Hot Flashes Shows Promise

Fezolinetant, an experimental medicine that doesn’t contain hormones, has successfully treated hot flashes.

3D Mammograms Reduce Risk of Advanced-Stage Disease in Women With Extremely Dense Breasts and High Risk of Breast Cancer

In women with extremely dense breasts and a high risk of breast cancer, screening with 3D mammograms — rather than 2D digital mammograms — was linked to a lower risk of advanced-stage disease.

Showing 24 of 1389